Last reviewed · How we verify
GLP-2
GLP-2 is a glucagon-like peptide-2 receptor agonist that enhances intestinal blood flow and promotes growth of the intestinal mucosa.
GLP-2 is a glucagon-like peptide-2 receptor agonist that enhances intestinal blood flow and promotes growth of the intestinal mucosa. Used for Short bowel syndrome, Intestinal failure-associated liver disease.
At a glance
| Generic name | GLP-2 |
|---|---|
| Also known as | glucagon like peptide 2 |
| Sponsor | University of Copenhagen |
| Drug class | GLP-2 receptor agonist |
| Target | GLP-2R |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
GLP-2 binds to GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, triggering increased mesenteric blood flow and stimulating proliferation of intestinal epithelial cells. This mechanism supports intestinal barrier function and nutrient absorption, making it therapeutically relevant for conditions characterized by intestinal dysfunction or mucosal atrophy.
Approved indications
- Short bowel syndrome
- Intestinal failure-associated liver disease
Common side effects
- Abdominal pain
- Nausea
- Injection site reactions
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US (PHASE2)
- Tirzepatide in MetALD (PHASE2)
- Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (PHASE2)
- Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes (PHASE3)
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLP-2 CI brief — competitive landscape report
- GLP-2 updates RSS · CI watch RSS
- University of Copenhagen portfolio CI